Voyager Therapeutics, Inc. Announces Board Changes, Effective April 28, 2023
February 23, 2023 at 06:01 am EST
Share
On February 22, 2023 (the Agreement Date"), Voyager Therapeutics, Inc. and Robert W. Hesslein entered into a Transition, Separation and Release of Claims Agreement (the Separation Agreement"), pursuant to which Mr. Hesslein resigned from his position of Senior Vice President and General Counsel and from any and all other positions he holds as an officer or employee of the Company or an officer, employee or director of any of its subsidiaries, effective on April 28, 2023, or such earlier date as may be mutually agreed upon in writing by the Company and Mr. Hesslein.
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Companyâs pipeline includes programs for Alzheimerâs disease, amyotrophic lateral sclerosis (ALS), Parkinsonâs disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreichâs Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimerâs disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.
VOYAGER THERAPEUTICS, INC. 
